Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

740 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B, Picard F, Mahe I, Hanon O, Touzé E, Danchin N, Lamy FX, Ricci L, Steg PG. Falissard B, et al. Among authors: picard f. Arch Cardiovasc Dis. 2019 Jun-Jul;112(6-7):400-409. doi: 10.1016/j.acvd.2019.02.003. Epub 2019 Apr 20. Arch Cardiovasc Dis. 2019. PMID: 31014991 Free article.
EvaluatioN of ApiXaban in strOke and systemic embolism prevention in patients with non-valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM study.
Picard F, Van Ganse E, Ducrocq G, Danchin N, Falissard B, Hanon O, Belhassen M, Ginoux M, Lefevre C, Cotte FE, Mahé I, Steg PG. Picard F, et al. Clin Cardiol. 2019 Oct;42(10):851-859. doi: 10.1002/clc.23231. Epub 2019 Jul 17. Clin Cardiol. 2019. PMID: 31313832 Free PMC article.
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial.
Silvain J, Lattuca B, Beygui F, Rangé G, Motovska Z, Dillinger JG, Boueri Z, Brunel P, Lhermusier T, Pouillot C, Larrieu-Ardilouze E, Boccara F, Labeque JN, Guedeney P, El Kasty M, Laredo M, Dumaine R, Ducrocq G, Collet JP, Cayla G, Blanchart K, Kala P, Vicaut E, Montalescot G; ALPHEUS investigators. Silvain J, et al. Lancet. 2020 Nov 28;396(10264):1737-1744. doi: 10.1016/S0140-6736(20)32236-4. Epub 2020 Nov 14. Lancet. 2020. PMID: 33202219 Free article. Clinical Trial.
Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry.
Picard F, Bhatt DL, Ducrocq G, Ohman EM, Goto S, Eagle KA, Wilson PWF, Smith SC Jr, Elbez Y, Steg PG. Picard F, et al. Int J Cardiol. 2021 Oct 1;340:96-104. doi: 10.1016/j.ijcard.2021.08.031. Epub 2021 Aug 25. Int J Cardiol. 2021. PMID: 34450192 Clinical Trial.
740 results